There is a concerted effort to identify biomarkers to understand the risk of progression of diabetic eye disease, but many studies have not been performed in diverse populations, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
There is a concerted effort to identify biomarkers to understand the risk of progression of diabetic eye disease, but many studies have not been performed in diverse populations, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
Transcript
You recently published on the need to study circulatory biomarkers in a more diverse population. Can you explain the issue of the lack of study into the performance of biomarkers in racially and ethnically diverse populations?
There's a huge unmet need for biomarkers that may help us better understand risk of progression and worsening of diabetic eye disease in our patients. Right now, we don't have great ways to predict who may lose vision, who may develop more advanced complications, aside from our classic Early Treatment Diabetic Retinopathy Study scale, which only looks at the vascular lesions of diabetes and doesn't include the entire retina, and it doesn't at all include things like neural retinal disease or visual function or the molecular pathways that may lead to disease.
I think there's a concerted effort going on these days, and some of this is being stood up by a project known as the Mary Tyler Moore Vision Initiative. The late Mary Tyler Moore was a remarkable film and TV actress who had type 1 diabetes who served as a very strong advocate for patients with diabetes throughout her life, and she lost a lot of vision because of diabetic retinopathy. So, in her honor and her memory, her husband Robert Levine has started a project trying to create platforms to help accelerate research and development of new therapeutics and preventions in the area of diabetic retinal disease.
As part of this we also recognize that many of our studies have been performed in populations that are not as diverse as we would ideally like to see. I think in future studies, looking across racially/ethnically diverse populations is really important, because we need to understand: Do biomarkers behave the same way across populations? How do we know when we can generalize the results of one study to global populations who may have very large needs in terms of diabetic retinopathy prevention and treatment?
Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD
May 2nd 2024Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More